| scholarly article | Q13442814 |
| P50 | author | Zhaohua Hou | Q58910992 |
| P2093 | author name string | C Zhang | |
| H Yang | |||
| W Xu | |||
| J Zhang | |||
| Y Guan | |||
| Z Tian | |||
| P Lan | |||
| P2860 | cites work | MicroRNA genes are transcribed by RNA polymerase II | Q24562649 |
| miR-17-92 cluster: ups and downs in cancer and aging | Q24617309 | ||
| Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis | Q24648286 | ||
| Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation | Q24649964 | ||
| Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 | ||
| Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells | Q25257349 | ||
| A microRNA polycistron as a potential human oncogene | Q27860720 | ||
| c-Myc-regulated microRNAs modulate E2F1 expression | Q27861046 | ||
| Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway | Q28115005 | ||
| Clinical development of histone deacetylase inhibitors as anticancer agents | Q28244438 | ||
| Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma | Q28260227 | ||
| E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer | Q28271985 | ||
| Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia | Q28306913 | ||
| Transcription factor GATA-3 is required for development of the T-cell lineage | Q28587190 | ||
| Histone acetylation and transcriptional regulatory mechanisms | Q29547707 | ||
| Cancer epigenetics: from mechanism to therapy | Q29614799 | ||
| Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas | Q33860585 | ||
| HDAC inhibition decreases the expression of EGFR in colorectal cancer cells | Q33862612 | ||
| Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes | Q33941116 | ||
| Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation | Q34109986 | ||
| microRNA regulation of inflammatory responses | Q34245279 | ||
| TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. | Q34428174 | ||
| Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene | Q35107914 | ||
| Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells | Q35203879 | ||
| The miR-17-92 microRNA cluster is regulated by multiple mechanisms in B-cell malignancies | Q35235849 | ||
| Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications | Q35734509 | ||
| Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1). | Q36315304 | ||
| Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy | Q36763539 | ||
| HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses | Q37073624 | ||
| Role of histone acetylation in cell physiology and diseases: An update | Q37769653 | ||
| Current strategies for microRNA research | Q37975146 | ||
| Wild-type p53 and p73 negatively regulate expression of proliferation related genes | Q38296687 | ||
| RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. | Q38703254 | ||
| Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest | Q39009811 | ||
| Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9. | Q39031748 | ||
| Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells | Q39281746 | ||
| High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia | Q39587664 | ||
| Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis | Q39896035 | ||
| Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. | Q39910403 | ||
| Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. | Q39954301 | ||
| Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. | Q40016772 | ||
| Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells | Q40082894 | ||
| Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2–M transition | Q40629817 | ||
| Intracellular poly(I:C) initiated gastric adenocarcinoma cell apoptosis and subsequently ameliorated NK cell functions | Q41863836 | ||
| miR146a impairs the IFN-induced anti-HBV immune response by downregulating STAT1 in hepatocytes | Q42281174 | ||
| Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors | Q42833178 | ||
| Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. | Q44564135 | ||
| Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells | Q46136496 | ||
| Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate | Q46604673 | ||
| MicroRNA mediated network and DNA methylation in colorectal cancer. | Q53168497 | ||
| Is histone deacetylase-9-MicroRNA-17~92 cluster a novel axis for angiogenesis regulation? | Q86111047 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 112-121 | |
| P577 | publication date | 2014-11-13 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma | |
| P478 | volume | 112 |
| Q64087318 | Analysis of promoter methylation and epigenetic regulation of miR-32 in colorectal cancer cells |
| Q35845089 | Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis |
| Q89975349 | Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure |
| Q33439523 | Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial |
| Q58755253 | Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review |
| Q39396613 | Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review |
| Q92068538 | DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses |
| Q47788129 | Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis |
| Q38749824 | Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy |
| Q41340663 | Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma |
| Q37734489 | Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes |
| Q38802155 | Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes. |
| Q48134207 | HDAC Inhibition Improves the Sarcoendoplasmic Reticulum Ca2+-ATPase Activity in Cardiac Myocytes. |
| Q45072959 | HDAC inhibitors enhance the immunotherapy response of melanoma cells |
| Q38763747 | Histone deacetylase inhibitors as immunomodulators in cancer therapeutics |
| Q58792092 | ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid |
| Q91727003 | Immunological Effects of Epigenetic Modifiers |
| Q38572855 | Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review |
| Q91951381 | Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets |
| Q47110491 | Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands? |
| Q37545100 | Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines. |
| Q37745098 | MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma |
| Q39061756 | MiR-17-92 cluster promotes hepatocarcinogenesis |
| Q41169679 | MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells |
| Q90479399 | MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers |
| Q50067809 | MicroRNAs in the Diagnosis and Treatment of Cancer. |
| Q38962024 | Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies |
| Q59795771 | Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications |
| Q42042886 | Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. |
| Q38527482 | Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy |
| Q89980594 | Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application |
| Q36211604 | Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study |
| Q40393432 | RNAi-mediated knockdown of MCM7 gene on CML cells and its therapeutic potential for leukemia |
| Q87148283 | Resminostat: Opening the door to epigenetic treatments for liver cancer |
| Q42371577 | Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway |
| Q47097862 | SIRT1 promotes tumor-like invasion of fibroblast-like synoviocytes in rheumatoid arthritis via targeting TIMP1. |
| Q33815894 | Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer |
| Q38799990 | Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression |
| Q38777547 | Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs |
| Q26746972 | Targeting microRNAs as key modulators of tumor immune response |
| Q90284614 | The Role of miRNAs in Immune Cell Development, Immune Cell Activation, and Tumor Immunity: With a Focus on Macrophages and Natural Killer Cells |
| Q64987018 | The Wnt/β-Catenin/LEF1 Pathway Promotes Cell Proliferation at Least in Part Through Direct Upregulation of miR-17-92 Cluster. |
| Q40130732 | The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity |
| Q90718904 | The role of cancer-derived microRNAs in cancer immune escape |
| Q64958587 | The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review. |
| Q26770165 | The urgent need to recover MHC class I in cancers for effective immunotherapy |
| Q50276385 | Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects |
| Q64066124 | Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma |
| Q99578626 | Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells |
| Q50186375 | Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells. |
| Q38622540 | [pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells |
| Q50976179 | microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells. |
Search more.